Literature DB >> 26841681

The Role of Clozapine in Treatment-Resistant Schizophrenia.

John M Kane1, Christoph U Correll1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26841681     DOI： 10.1001/jamapsychiatry.2015.2966

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN： 2168-622X            Impact factor:   21.596


× No keyword cloud information.
  17 in total

1.  Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies.

Authors:  Takahiro Masuda; Fuminari Misawa; Masayuki Takase; John M Kane; Christoph U Correll
Journal:  JAMA Psychiatry       Date:  2019-10-01       Impact factor: 21.596

Review 2.  Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria.

Authors:  Robin Murray; Christoph U Correll; Gavin P Reynolds; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2017-03-01

3.  Clozapine for Treatment-Resistant Schizophrenia: Still the Gold Standard?

Authors:  David M Taylor
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

4.  Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group.

Authors:  Elias Wagner; John M Kane; Christoph U Correll; Oliver Howes; Dan Siskind; William G Honer; Jimmy Lee; Peter Falkai; Thomas Schneider-Axmann; Alkomiet Hasan
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

Review 5.  Clozapine and Gastrointestinal Hypomotility.

Authors:  Dan Cohen
Journal:  CNS Drugs       Date:  2017-12       Impact factor: 5.749

Review 6.  Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives.

Authors:  Frederick C Nucifora; Edgar Woznica; Brian J Lee; Nicola Cascella; Akira Sawa
Journal:  Neurobiol Dis       Date:  2018-08-29       Impact factor: 5.996

7.  Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring.

Authors:  Ryan S Sultan; Mark Olfson; Christoph U Correll; Erica J Duncan
Journal:  J Clin Psychiatry       Date:  2017 Sep/Oct       Impact factor: 4.384

Review 8.  The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses.

Authors:  Peter M Haddad; Christoph U Correll
Journal:  Ther Adv Psychopharmacol       Date:  2018-10-08

Review 9.  Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.

Authors:  Oliver D Howes; Rob McCutcheon; Ofer Agid; Andrea de Bartolomeis; Nico J M van Beveren; Michael L Birnbaum; Michael A P Bloomfield; Rodrigo A Bressan; Robert W Buchanan; William T Carpenter; David J Castle; Leslie Citrome; Zafiris J Daskalakis; Michael Davidson; Richard J Drake; Serdar Dursun; Bjørn H Ebdrup; Helio Elkis; Peter Falkai; W Wolfgang Fleischacker; Ary Gadelha; Fiona Gaughran; Birte Y Glenthøj; Ariel Graff-Guerrero; Jaime E C Hallak; William G Honer; James Kennedy; Bruce J Kinon; Stephen M Lawrie; Jimmy Lee; F Markus Leweke; James H MacCabe; Carolyn B McNabb; Herbert Meltzer; Hans-Jürgen Möller; Shinchiro Nakajima; Christos Pantelis; Tiago Reis Marques; Gary Remington; Susan L Rossell; Bruce R Russell; Cynthia O Siu; Takefumi Suzuki; Iris E Sommer; David Taylor; Neil Thomas; Alp Üçok; Daniel Umbricht; James T R Walters; John Kane; Christoph U Correll
Journal:  Am J Psychiatry       Date:  2016-12-06       Impact factor: 18.112

10.  Behavioral outputs of negative symptom domains of schizophrenia.

Authors:  Octavia Căpățînă; Mihaela Fadgyas Stănculete; Ioana Micluția
Journal:  Exp Ther Med       Date:  2021-05-26       Impact factor: 2.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.